Literature DB >> 1598662

[The percutaneous irradiation of osteolytic bone metastases--a course assessment].

W Weber1, H P Rösler, G Doll, M Dostert, J Kutzner, H Schild.   

Abstract

Percutaneous radiotherapy is the most effective modality for treatment of metastatic bone cancer. Local irradiation improves overall quality of life by relieving pain in most patients. It also helps preventing complications as pathological fractures in lytic bone lesions by new bone formation. In a retrospective study on 100 patients, irradiated for lytic bone metastases, the radiotherapeutic effect on alleviation of pain and on recalcification rate was investigated. In our experience in 84% of the cases pain and disability associated with bone metastases could be decreased. 38% of the patients had complete relief of symptoms. A correlation between subjective therapy effect and histology of the primary tumor was not demonstrated. Remineralization was found in 67% of all irradiated skeletal areas (n = 137) (recalcification rate in breast cancer 77%, in bronchial carcinoma 27%, and in renal cell carcinoma 25%). After a total dose of 30 Gy reduction of the metastases-associated pain was achieved in 81% of the cases and remineralization was observed in 70% of the cases.

Entities:  

Mesh:

Year:  1992        PMID: 1598662

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  2 in total

1.  Assessment of the risk factors for impending fractures following radiotherapy for long bone metastases using CT scan-based virtual simulation: a retrospective study.

Authors:  Zuzana Tatar; Martin Soubrier; Anne Françoise Dillies; Pierre Verrelle; Stéphane Boisgard; Michel Lapeyre
Journal:  Radiat Oncol       Date:  2014-10-16       Impact factor: 3.481

2.  Effects of Radiotherapy in the treatment of multiple myeloma: a retrospective analysis of a Single Institution.

Authors:  Christiane Matuschek; Thomas A Ochtrop; Edwin Bölke; Ute Ganswindt; Roland Fenk; Stephan Gripp; Patric Kröpil; Peter Arne Gerber; Kai Kammers; Jackson Hamilton; Klaus Orth; Wilfried Budach
Journal:  Radiat Oncol       Date:  2015-03-28       Impact factor: 3.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.